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ABSTRACT 
BACKGROUND/PURPOSE: Conducting randomized controlled trial (RCT) for each of 
the risk factors associated with prophylactic pancreatic duct stent (PPDS) for 
post-ERCP pancreatitis (PEP) is difficult owing to the volume of cases and ethical 
considerations.  
In this study, we tried to reveal the degree of preventive effects of PPDS for each 
individual risk factor within the high-risk group of PEP using the propensity score 
analysis. 
METHODS: The clinical data of 1131 ERCP practices performed at Kobe University 
Hospital from April 2006 to February 2009 were collected prospectively. We 
investigated their clinical characteristics including the risk factors of PEP, the use of 
PPDS and complications of ERCP. We conducted the stratification analysis using the 
propensity score matching analysis. 
RESULTS: In 210 propensity score-matched ERCPs, PPDS proved to be effective in 
preventing PEP in patients with a history of pancreatitis (odds ratio 0.11, 95% CI 
0.01-0.76, p=0.01) and cases of difficult cannulation (requiring more than 30 minutes) 
 (odds ratio 0.13, 95% CI 0.01-1.14, p=0.08). 
CONCLUSIONS: Patients with a history of pancreatitis and cases of difficult cannulation 
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are strongly recommended for PPDS placement. The propensity score analysis can be 
adapted to the ERCP-related analysis with many procedure-related factors with using 
retrospective data, and may be adapted to investigate the matters that are unsuitable 
for RCT by volume and ethical issue. 
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INTRODUCTION 
It is considered that a prophylactic pancreatic duct stent (PPDS) prevents Post-ERCP 
pancreatitis (PEP) by preserving pancreatic juice flow 1-6, and as the results of 
randomized controlled trials and meta-analyses show, evidence of the efficacy of 
pancreatic stents for reducing PEP continues to accumulate. 4, 7-8 The latest 
meta-analysis estimated the relative risk of pancreatic stent placement in PEP as being 
0.32 (95% confidence interval 0.19-0.52; p<0.001). 8 In the guidelines for prophylaxis of 
PEP from the European Society of Gastrointestinal Endoscopy (ESGE), PPDS is in 
recommendation grade A in patients who are at high risk for the development of PEP. 9 
However, never PPDS is placed in all high-risk patients of PEP in real clinical practice. 
The use of PPDS was reported to be less widespread in the European investigation. 10 
There was a blatant discrepancy between the scientific evidence and the routine use of 
PPDS.  
One of the reasons is thought that it is not apparent which group receives the most 
preventive effects from PPDS within the high-risk group of PEP. In order to clarify the 
appropriate application of PPDS, it is important to reveal the degree of preventive 
effects for each individual risk factor within the high-risk group of PEP. 
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However, conducting RCT for each of the risk factors associated with PEP may be 
difficult owing to the volume of cases and ethical considerations, especially in 
ERCP-related procedure which is affected by intraoperative decision. 
Therefore, in the present study, we used propensity score analysis which is one of 
statistical analysis methods for being adapted for retrospective data. The propensity 
score analysis can balance the effects of many latent confounding risk factors with the 
element of intraoperative techniques within it.  
In this study, we tried to reveal the degree of preventive effects of PPDS for each 
individual risk factor within the high-risk group of PEP. 
 
METHODS 
Patients 
The clinical data of 1131 ERCP practices performed at Kobe University Hospital from 
April 2006 to February 2009 were collected prospectively. We investigated their clinical 
characteristics, including the risk factors of PEP, the use of PPDS and complications of 
ERCP. 
In this study, the risk factors of PEP are defined as follows considering the European 
Society of Gastrointestinal Endoscopy (ESGE) Guidelines: female gender, difficulty with 
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cannulation (requiring 15~30 minutes, more than 30 minutes), total procedure time 
(requiring 30~60 minutes, more than 60 minutes), pancreatic duct injection, pancreatic 
IDUS, pancreatic juice cytodiagnosis, pancreatic duct brush cytodiagnosis, pre-cut 
sphincterotomy, previous pancreatitis, and suspected SOD. 7, 11 
The definition of PEP was standardized by a consensus conference held in 1991, and 
those criteria have become widely accepted. 5 PEP was defined as pancreatic pain and 
hyperamylasemia within 24 hours of the procedure. Pancreatic pain was defined as 
persistent pain in the epigastric or periumbilical region. Hyperamylasemia was defined 
as an increase in serum amylase to more than 3 times the upper normal limit defined by 
our institution (37-102 U/l). 5, 12 
Patients whose papillae were unphysiological (as follows) were excluded from this 
study: (1) previous endoscopic sphincterotomy or papillary balloon dilation, (2) pancreas 
divisum, (3) tumor of papilla of Vater, (4) endoscopic nasopancreatic drainage 
(ENPD)/pancreatic stent (no spontaneous dislodgement), or (5) 
post-pancreaticoduodenectomy. 
This study was conducted in accordance with the Declaration of Helsinki and its 
amendments (UMIN-CTR ID: 000007332). This study protocol was approved by the 
Kobe University School of Medicine Ethics Committee (No.1283).  
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All authors had access to the study data and had reviewed and approved the final 
manuscript. 
ERCP 
ERCPs were performed by the four operators with experience of more than 500 ERCP 
cases. In our ERCP practice, the proportion of therapeutic procedures was 
approximately 65%. After the procedure, patients continued fasting until the next 
morning with a drip infusion. All patients received an infusion of protease inhibitor 
(nafamostat mesilate, 20 mg/day) and antibiotics for 2 days. Serum amylase levels were 
measured at baseline, 4 hours later, and 18-24 hours later.  
PPDS 
Use of a PPDS was attempted when the operator judged that it was necessary, having 
considered that the case had become a high-risk case of PEP.  
The PPDS procedure was carried out using a 5F polyethylene stent (Cook Endoscopy, 
Inc., Winston-Salem, NC). In all cases, stent dislodgments were confirmed by 
abdominal radiographs taken within 7 days after the ERCP. If the stent had not been 
dislodged, it was removed using the duodenoscope. 
Statistical analysis 
The difference in the incidence of PEP between the stent group and the non-stent group 
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was analyzed by chi-squared test or Fisher’s exact test. The differences of other clinical 
characteristics between the two groups were analyzed by chi-squared test or Fisher’s 
exact test for categorical variables, and were analyzed by a t-test for continuous 
variables.  
To elucidate the usefulness of PPDS for the prevention of PEP, propensity score 
matching analysis was performed because PPDS was used in selected patients in this 
study. The propensity scores of PPDS were generated by a multivariate logistic 
regression model 13-15 using the possible confounders (i.e. age, sex, difficulty of 
cannulation, total procedure time, pancreatic duct injection, pancreatic IDUS, biliary 
IDUS, pancreatic juice cytodiagnosis, biliary juice cytodiagnosis, pre-cut sphicterotomy, 
endoscopic sphincterotomy, suspected SOD, and previous pancreatitis). 
Although difficult cannulation was defined as that requiring greater than 30 minutes for 
cannulation according to a previous report 1, 95.4%(1079/1131) cases in our cases 
were intubated within 30 minutes. (Table 2) So, difficulties of cannulation were divided 
into three categories: requiring 0-15 minutes (as reference) /15-30 minutes/more than 
30 minutes. 
The differences between 0-15 minutes and 15-30 minutes, 0-15 minutes and 30- 
minutes were analyzed.   
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Total procedure times were also categorized into three groups: requiring 0-30 
minutes/30-60 minutes/more than 60 minutes. 
The propensity score was calculated for each patient based on a logistic regression 
analysis of the probability of PPDS using clinical characteristics. With these propensity 
scores, we used matching technique to create a 1-to-1 match of cases with controls. 
Specifically, using the propensity scores, one-to-one matching 13 with nearest neighbor 
approach, a “greedy” approach where the closest control match for each treated unit is 
chosen one at a time,16 was performed for the stent group and the non-stent group 
(Figure 1).  
C-statistic calculated by the receiver operating characteristic curve of our model was 
0.78, showing that our model had good ability to distinguish stent-use patients from 
non-stent-use patients. After the matching, the incidences of PEP were compared 
between the matched stent group and the matched non-stent group. Subgroup 
analyses limited to high-risk patients were also performed. Influences of risk factors 
were estimated by odds ratio with a 95% confidence interval. All analyses were 
performed using R version 2.12 (R Foundation for Statistical Computing, Vienna, 
Austria). For all analyses, p values <0.05 were considered statistically significant. 
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RESULTS 
PPDS 
Of 1131 ERCPs, PPDS placements were attempted in 105 (9.0%) ERCPs. Table 1 
shows a summary of stent placements. With regard to the frequency of PPDS attempts, 
the risk factor for which PPDS was attempted at the highest frequency was pre-cut 
sphincterotomy (37.5%, 6/16), followed by pancreatic IDUS (26%, 17/65), pancreatic 
brush cytodiagnosis (21.7%, 20/92), and suspected SOD (20%, 4/20).  
The proportion of ERCPs in which PPDS was attempted according to the number of risk 
factors of PEP is shown in Figure 2. With increased number of risk factors, the 
frequency of PPDS placement became higher. As a result, the cases that the operator 
judged to insert PPDS having considered that the case had become a high-risk case of 
PEP had included many risks. 
Patient characteristics 
The characteristics of the stent group and the non-stent group are shown in Table 2. 
There were significant differences in cannulation difficulty, total procedure time, the 
proportion of patients with pancreatic duct injection, pancreatic IDUS, pancreatic duct 
brush cytodiagnosis, and pre-cut sphincterotomy between the two groups. 
With regard to the final diagnoses of both groups, significant differences between the 
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two groups were observed in the proportions of patients with cholangiocellular 
carcinoma, intraductal papillary mucinous neoplasm (IPMN), and pancreatic cancer. 
Post–ERCP pancreatitis 
The overall frequency of PEP was 8.4% (95 of 1131). PEP occurred in 5.9% of the stent 
group and 9% of the non-stent group (p=0.63) (Table 3). To minimize the effect of 
selection bias between the two groups, propensity score matching analysis was 
performed, and 105 matched cases in the non-stent group corresponding to 105 cases 
in the stent group were chosen in a one-to-one manner. After the matching, there were 
no significant differences in the clinical characteristics of the patients, including for the 
risk factors of PEP, between the two groups (Table 2), and the incidence of PEP in the 
matched stent group was significantly lower than that in the matched non-stent group 
(6% vs. 18%, p=0.02, odds ratio 0.32, 95% CI 0.12-0.77) (Table 3). 
Stratification analysis on preventive efficacy of PPDS in each factors within the 
high-risk group of PEP 
Considering the odds ratio of the patients with each factor, the stratification analysis on 
preventive efficacy of PPDS in each factor within the high-risk group of PEP revealed 
that PPDS proved to be effective in preventing PEP in patients with a history of 
pancreatitis (odds ratio 0.11, 95% CI 0.01-0.76, p=0.01) and in cases of difficult 
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cannulation (requiring more than 30 minutes) (odds ratio 0.13, 95% CI 0.01-1.14, 
p=0.08) (Figure 3). 
 
DISCUSSION 
In order to clarify the refined application of PPDS, it is important to determine which 
factors are more highly associated with preventive effects of PPDS within the high-risk 
group of PEP. However, an adequate number of stratification analyses for each factor by 
RCT have not been carried out. A reason for this is that it is virtually impossible to 
conduct RCT for each of the many risk factors associated with PEP owing to the limited 
number of subjects that can be enrolled for each risk factor; this is especially true for the 
rarer risk factors. Moreover, there is ethical issue that RCT study is performed on 
high-risk patients of PEP. Furthermore, in cases of investigations on ERCP related 
events such as PEP in which intraoperative techniques are major influencing factor, 
even with RCT, it may not be possible to adjust completely for these biases. 
This is a significant difference from similar investigations conducted on medications, 
and these biases—related to intraoperative technique—may influence the outcome and 
mask the true efficacy of PPDS.  
Therefore, in this study, we used a propensity score matching analysis to minimize the 
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effects of any inherent biases. Propensity score methods are used for reducing the 
effects of confounding in observational studies, and can be powerful tools in assessing 
average treatment effects in observational studies.13, 17,18 Recent study has reported 
that treatment effects from randomized trials and propensity score analyses were similar 
in similar populations.19 
In the present study, we effectively adjusted for biases in the clinical data that we had 
accumulated prospectively. After the matching, no differences in the clinical 
characteristics of the patients, including the risk factors of PEP, were observed. The risk 
reduction rate of PPDS for the development of PEP was found to be 68% (odds ratio 
0.32). Here the results obtained from the propensity score analysis—adjusting for 
biases—were comparable to those presented in previous RCT studies. 
In stratification analysis on preventive efficacy of PPDS in each factors within the 
high-risk group of PEP, we found that the rate of PEP in the patients with a history of 
pancreatitis was significantly reduced by PPDS (p = 0.01). The odds ratio (OR = 0.11) 
was lower than that of the whole data (a vertical line in Figure 2: OR = 0.32). Additionally, 
the confidence intervals in this group (95%CI = 0.01-0.76) were less than 1. From these 
results, it was thought that the patients with a history of pancreatitis are the most 
recommended group for PPDS among the high-risk group of PEP.  
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With regard to cases of difficult cannulation, the odds ratio in this group (OR = 0.13) was 
lower than that of the whole data (OR = 0.32) (Figure 3).  
There was not the technical influence of the operators in this result, because the rates of 
the cases requiring more than 30 minutes in each operators did not have the difference 
(operator A:4%17/425, B:5.2% 20/384, C:4.7% 8/170, D:4.6% 7/152). 
This result was not statistically significant (p = 0.08), but it was thought that cases of 
difficult cannulation are particularly recommended for PPDS within the high-risk group of 
PEP.  
We strongly recommend insertion of a PPDS in patients with a history of pancreatitis 
and cases of difficult cannulation. 
With regard to the group with pancreatic duct injection, the rate of PEP in the stent 
group was significantly lower than that in the no-stent group (p = 0.01). The odds ratio of 
this group was the same as that for all the data because almost all cases were 
approximately contrasted in terms of pancreatic duct. 
The present study has some limitations. First, it was difficult to show the preventive 
efficacy in pancreatic IDUS cases and cases with suspected SOD because the number 
of these cases was limited. Second, although we evaluated the effects of the risk factors 
for PEP from the ESGE Guidelines, the effects of other factors such as younger age and 
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degree of pancreatic duct filling were not assessed in this study. Third, we cannot adjust 
for unknown factors by propensity score analysis.  
 
Conclusion 
We effectively adjusted for biases in the clinical data that we had accumulated 
prospectively and conducted stratification analysis on the preventive effects with PPDS 
in the high-risk group of PEP. This study also strongly suggests that patients with a 
history of pancreatitis and cases of difficult cannulation are particularly recommended 
for PPDS placement within the high-risk group of PEP. The propensity score analysis 
can be adapted to the ERCP-related analysis with many procedure-related factors with 
using retrospective data, and may be adapted to investigate the matters that are 
unsuitable for RCT by volume and ethical issue. 
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Figure Legends 
Figure 1 
Schematic representation of the propensity score matching analysis in this study. 
In an effort to balance the patient groups, we used propensity score analysis to 
generate a set of matched cases (patients with PPDS) and controls (patients without 
stent).  
The propensity score was calculated for each 1031 patients based on a logistic 
regression analysis of the probability of PPDS using clinical characteristics. 
Using propensity scores, we selected 105 patients from 1026 patients without stent, and 
generated 105 sets of matched cases. 
 
Figure 2 
The proportion of ERCPs in which use of a PPDS was attempted according to the 
number of risk factors of PEP. With increasing number of risk factors, the frequency at 
which use of a PPDS was performed became higher. 
 
Figure 3 
The stratification analysis on preventive efficacy of PPDS in each factors within the 
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high-risk group of PEP (S VS. m-N). A vertical line represents the odds ratio of the whole 
data. The odds ratio in patients with a history of pancreatitis (OR = 0.11) was lower than 
that for the whole data (a vertical line in Figure 3: OR = 0.32). Additionally, the 
confidence interval in this group (95%CI = 0.01-0.76) was less than 1. From these 
results, it was thought that the patients with a history of pancreatitis are those most 
recommended to receive PPDS among patients in the high-risk group of PEP. 
Furthermore, the odds ratio in cases of difficult cannulation (requiring more than 30 
minutes) (OR = 0.13) was lower than that for the whole data. This result was not 
statistically significant, but it was thought that cases of difficult cannulation are 
particularly recommended for PPDS within the high-risk group of PEP. 
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Table 1 Summary of PPDS placement 
 
Number of patients in whom a PPDS insertion was attempted 105 
Number of patients in whom a PPDS was placed 102 (97.0%) 
Dislodgement  
Spontaneous dislodgement 96 (94.1%) 
Endoscopic removal 6 (5.9%) 
The mean duration of dislodgement (day) 2.0 
Complications  
Migration 0 (0%) 
Hemorrhage 0 (0%) 
Perforation 0 (0%) 
PEP 6 (5.9%) 
 
PPDS: prophylactic pancreatic duct stent 
PEP: post-endoscopic retrograde cholangiopancreatography pancreatitis 
 
Table 2 Characteristics of patients 
 
 Stent group Non-stent group Non-stent group (after matching) 
 n=105 n=1026 n=105 
Mean age (±SD) 66±13 65±12 68±11 
Male/female 65/40 658/368 65/40 
Time required for cannulation    
                    0~15min 59 (58%) 767 (74.5%) a 51 (48.6%) 
                   15~30min 31 (29%) 222 (21.7%) 38 (36.2%) 
30~min 15 (13%) 37 (3.8%) 16 (15.2%) 
Total procedure time    
                    0~30min 23 (22%) 314 (31%) a 22 (21%) 
                   30~60min 41 (39%) 506 (49%) 41 (39%) 
                   60~min 41 (39%) 206 (20%) 42 (40%) 
Pancreatic duct injection 103 (98%) 705 (69%) a 102 (97%) 
Pancreatic IDUS 17 (16%) 48 (5%) a 11 (10%) 
Biliary IDUS 14 (13%) 89 (8%) 12 (11%) 
Pancreatic juice cytodiagnosis 15 (14%) 108 (11%) 10 (10%) 
Biliary juice cytodiagnosis 4 (4%) 62 (6%) 6 (6%) 
Pancreatic duct brush cytodiagnosis 20 (19%) 72 (7%) a 20 (19%) 
Biliary duct brush cytodiagnosis 14 (13%) 104 (10%) 9 (9%) 
Precut sphincterotomy 6 (6%) 10 (1%) b 5 (5%) 
Endoscopic sphincterotomy 14 (14%) 92 (9%) 14 (14%) 
previous pancreatitis c 11 (10%) 79 (8%) 15 (14.2%) 
Suspected SOD 4 (3.8%) 16 (1.6%) 5 (4.7%) 
p-value: t-test for continuous variables, χ-squared test or Fisher’s exact test for categorical variables 
 
SD: standard deviation 
IDUS: intraductal ultrasonography 
SOD: sphincter of oddi dysfunction 
a p<0.001 vs. Stent group 
b p<0.01 vs. Stent group 
c Acute exacerbation of chronic pancreatitis in 13 patients (2 in the stent group, 11 in the non-stent group, 1 in the 
non-stent group after matching) 
Table 3 The details of PEP 
 
 All cases Stent group Non-stent group Non-stent group (after matching) 
p-value 
(Odds ratio : 95% CI) 
 n=1131 n=105 n=1026 n=105 S VS. N S VS. m-N 
PEP (%) 95 (8.4%) 6 (5.9%) 89 (9%) 19 (18%) 0.63 0.02 
(0.32 : 0.12-0.77)
p-value: χ-squared test 
 
PEP: post-endoscopic retrograde cholangiopancreatography pancreatitis 
CI: confidence interval 
S: stent group 
N: non-stent group 
m-N: non-stent group (after matching) 
 
 



